Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma (Q46720756)

24 December 2017

title

Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma (English)

1 reference

24 December 2017

author name string

Gerull S

1

1 reference

24 December 2017

Goerner M

2

1 reference

24 December 2017

Benner A

3

1 reference

24 December 2017

Hegenbart U

4

1 reference

24 December 2017

Klein U

5

1 reference

24 December 2017

Schaefer H

6

1 reference

24 December 2017

Goldschmidt H

7

1 reference

24 December 2017

Ho AD

8

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

24 December 2017

Bone Marrow Transplantation

published in

1 reference

24 December 2017

volume

36

1 reference

24 December 2017

issue

11

1 reference

24 December 2017

page(s)

963-969

1 reference

24 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705161

exact match

0 references

cites work

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

Treatment approaches for relapsing and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

Allogeneic hematopoietic cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

Reduced intensity conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

Cox's Regression Model for Counting Processes: A Large Sample Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

Follow‐up of patients with progressive multiple myeloma undergoing allografts after reduced‐intensity conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

Dissociation of putative graft‐versus‐haematopoiesis and graft‐versus‐myeloma effects in patients with rapidly progressive multiple myeloma*

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

7 January 2021

Treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

7 January 2021

Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

7 January 2021

Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

7 January 2021

Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

7 January 2021

Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

7 January 2021

Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

7 January 2021

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

7 January 2021

Non-myeloablative transplants for malignant disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

7 January 2021

High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

7 January 2021

Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

7 January 2021

Censoring distributions as a measure of follow-up in survival analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705161

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1705161

1 reference

24 December 2017

Dimensions Publication ID

0 references

1 reference

24 December 2017